Cover Image

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Frenking, Jan (Author) , Zhou, Xiang (Author) , Rejeski, Kai (Author) , Wagner, Vivien (Author) , Costello, Patrick (Author) , Hielscher, Thomas (Author) , Gatti, Lilan (Author) , Kauer, Joseph (Author) , Nadeem, Omar (Author) , Mai, Elias K. (Author) , Michel, Christian S. (Author) , Friedrich, Mirco (Author) , Sedloev, David (Author) , Weinhold, Niels (Author) , Goldschmidt, Hartmut (Author) , Herfarth, Klaus (Author) , Schmitt, Anita (Author) , Hundemer, Michael (Author) , Schmitt, Michael (Author) , Müller-Tidow, Carsten (Author) , Topp, Max (Author) , Einsele, Hermann (Author) , Dreger, Peter (Author) , Munshi, Nikhil C. (Author) , Sperling, Adam S. (Author) , Rasche, Leo (Author) , Sauer, Sandra (Author) , Raab, Marc-Steffen (Author)
Format: Article (Journal)
Language:English
Published: August 26 2025
In: Blood advances
Year: 2025, Volume: 9, Issue: 16, Pages: 4151-4166
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024015732
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2024015732
Get full text
Author Notes:Jan H. Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Thomas Hielscher, Lilan Gatti, Joseph Kauer, Omar Nadeem, Elias K. Mai, Christian S. Michel, Mirco J. Friedrich, David Sedloev, Niels Weinhold, Hartmut Goldschmidt, Klaus Herfarth, Anita Schmitt, Michael Hundemer, Michael Schmitt, Carsten Müller-Tidow, Max Topp, Hermann Einsele, Peter Dreger, Nikhil C. Munshi, Adam S. Sperling, Leo Rasche, Sandra Sauer, and Marc S. Raab
Description
Summary:Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR-T therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents), or intensive CTX (≥3 CTX agents or high-dose therapy with stem cell transplantation). We found associations between the number of CTX agents used and impaired post-CAR-T hematopoietic reconstitution, evident across hematopoietic cell lineages and particularly manifesting during the late post-CAR-T period. Intensive CTX bridging was associated with a prolonged time to neutrophil and platelet recovery, distinct patterns of hematopoietic recovery (eg, an intermittent phenotype characterized by a second drop), an increased susceptibility to severe infections and a significantly increased risk for severe late cytopenias in univariate and multivariate models. Taken together, these results highlight that bridging intensity distinctly shapes the trajectory of hematopoietic recovery after BCMA CAR-T therapy. Targeted and novel immunotherapies could provide alternatives for bridging, and high-risk patients may particularly benefit from enhanced monitoring, prophylaxis, and supportive care.
Item Description:Online veröffentlicht: 14. August 2025
Gesehen am 15.12.2025
Physical Description:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024015732

Similar Items